# Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna

> **NCT01088737** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Medical University of Graz** · enrollment: 60 (actual)

## Conditions studied

- Lentigo Maligna

## Interventions

- **DRUG:** Imiquimod

## Key facts

- **NCT ID:** NCT01088737
- **Lead sponsor:** Medical University of Graz
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01088737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01088737, "Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01088737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*